Leearne Hinch

CEO of INOVIQ Ltd (@INOVIQltd)
Biotechnology executive (@leearnehinch)

[Leearne Hinch @leearnehinch]

@INOVIQLtd is collaborating with @UQ_News to develop INOVIQ’s EXO-OC screening test for the early detection of ovarian cancer.

To read the Channel 9 News article visit: https://t.co/2leZdJzB9L

#INOVIQ #OvarianCancer #EXOOC #OvarianCancerScreening #Diagnostics #Channel9News

[UQ News @UQ_News]

Clinical trials, led by @cfsalomo, of a simple blood test to detect early-stage ovarian cancer – key to boosting survival rates – will begin at #UQ later this year. @UQMedicine

📖 https://t.co/0uMygp7FdC

[Leearne Hinch @leearnehinch]

To see my full interview with #ShareCafe about the breakthrough results for @INOVIQLtd's ovarian cancer test, follow the link in their post. Also, don’t forget to register for Share Cafe’s Hidden Gems “Sip and Learn” webinar on Friday, 13 Dec, where I’ll be presenting.

[INOVIQ Ltd (ASX:IIQ) @INOVIQLtd]

On Friday, 6 December, @INOVIQLtd CEO, Dr. @leearnehinch was interviewed by Share Cafe about our breakthrough results for INOVIQ’s ovarian cancer test.

Catch the full interview here: https://t.co/STqpaM1yFD

Don’t forget to register for the Share Cafe Hidden Gems Webinar (“Sip and Learn”) on Friday, 13 December at 12:30 PM, where Dr. Hinch will be presenting.

Register for the webinar here: https://t.co/fp3NSSPvVP

#OvarianCancer #CancerResearch #MedicalInnovation #Healthcare #Webinar #INOVIQ #Breakthrough #ShareCafe #HiddenGems #SmallCaps #Biotech #Diagnostics #Therapeutics

[Leearne Hinch @leearnehinch]

@INOVIQLtd successfully completed disease-specificity testing for breast cancer.

[INOVIQ Ltd (ASX:IIQ) @INOVIQLtd]

@INOVIQLtd has successfully completed disease-specificity testing for breast cancer.

The test has been analytically and clinically validated to detect breast cancer across all stages (81% sensitivity and 93% specificity), key breast cancer types and subtypes, and is effective for breast cancer monitoring.

This simple, accurate, and affordable blood test was developed using a widely utilised CA15-3 monoclonal antibody and INOVIQ’s SubB2M detection reagent. By specifically targeting neuCA15-3 conjugated CA15-3 produced by cancer cells, the test enhances cancer specificity and reduces the likelihood of false positives. The purpose of this study was to show the neuCA15-3 test was positive for cancer and had low false positives for non-cancer diseases and healthy. The results were negative for 97.4% of non-breast cancer samples, confirming the test specificity for breast cancer.

CEO, @leearnehinch said: “The test is being developed as an LDT for the US market initially. Demonstrating the specificity of neuCA15-3 for breast cancer detection completes another component of the test validation. The next step towards commercialising the neuCA15-3 test is to transfer and optimise the test on a system compatible with high-throughput commercial diagnostic instruments.”

Read more here: https://t.co/sR00GxYfoh

#INOVIQ #SubB2M #neuCA153 #BreastCancer #CancerDiagnostics #BloodTest #HealthcareInnovation #EarlyDetection #MedicalResearch #CancerResearch

[Leearne Hinch @leearnehinch]

@INOVIQLtd releases outstanding results for its EXO-OC ovarian cancer screening blood test.

[INOVIQ Ltd (ASX:IIQ) @INOVIQLtd]

@INOVIQLtd has achieved a significant milestone for its EXO-OC ovarian cancer screening test. An independent patient validation study in over 500 samples validated the test’s biomarkers and diagnostic performance, detecting ovarian cancer across all stages with overall accuracy of 94% and sensitivity of 92% at 96% specificity.

In the study, exosomes were isolated from more than 500 blood samples using INOVIQ’s EXO-NET® on a fully-automated high-throughput robotic platform. Ovarian cancer biomarkers were measured using targeted mass spectrometry, a technology that can be implemented in pathology laboratories worldwide.

When these high-performing EXO-NET®-isolated biomarkers were combined in cross-validated machine learning algorithms, the overall test accuracy exceeded 94%. At a test specificity set at 96%, the sensitivity was 92% for all stages of ovarian cancer and 91% for Stage I alone.

The next steps are to optimize the EXO-OC test on the instrument platform and perform additional clinical validation to deliver the test in a clinical laboratory.

CEO @leearnehinch said: “This biomarker panel showed outstanding performance in detecting early-stage ovarian cancer, where accurate diagnosis is most critical for improving patient outcomes. Early detection enables timely intervention, which is crucial for increasing survival rates and reducing disease progression.”

To read more go to: https://t.co/TB4IZNuzMD

#INOVIQ #OvarianCancer #CancerScreening #EXOOC #EXONET #Diagnostics #HealthcareInnovation #MedicalBreakthrough #Pathology #WomensHealth #CancerResearch #EarlyDetection #Biomarkers #CancerAwareness #PrecisionMedicine

[Leearne Hinch @leearnehinch]

@NextInvestors @INOVIQLtd Great to see StocksDigital investing in the future of @INOVIQLtd exosome research tools, diagnostics and therapeutics portfolio. Join us for the journey to improve patient outcomes for cancer!

[Leearne Hinch @leearnehinch]

Join me on Thursday, 13 June when I'll present at MST Access "Hidden Gems in Life Sciences" webinar.

Registration details are in @INOVIQLtd post.

[INOVIQ Ltd (ASX:IIQ) @INOVIQLtd]

Join @INOVIQLtd CEO, @Leearnehinch as she presents at the MST Access Hidden Gems in Life Sciences webinar on Thursday, 13 June 2024, at 3:00PM (AEST).

Register here: https://t.co/8IK7qItHrH

#INOVIQ #MSTFinancial #Webinar #LifeSciences #HiddenGems #Biotech #SmallCaps #Presentation #CancerResearch #Exosomes

[Leearne Hinch @leearnehinch]

If you missed the live event at the @sharecafetweets– Hidden Gems Webinar, simply click on the link in @INOVIQLtd's post.

[INOVIQ Ltd (ASX:IIQ) @INOVIQLtd]

@INOVIQLtd CEO @Leearnehinch delivered a well-received presentation at the @ShareCafeTweets – Hidden Gems Webinar. If you missed the live event, you can catch up by visiting https://t.co/X7y6WOmQ6W

#Presentation #Webinar #ShareCafe #Exosomes #EXONET #CancerResearch #Science

[Leearne Hinch @leearnehinch]

Join @INOVIQLtd and @promega on 28 February 2024 to learn about our complete EXO-NET high-throughput exosome isolation and RNA extraction solution for biomarker discovery and diagnostics development.

[INOVIQ Ltd (ASX:IIQ) @INOVIQLtd]

@INOVIQLtd CSO, Greg Rice (@IIQ_CSO) presents @Promega Webinar on 28 Feb 2024 at 12:00PM SGT and 1:00PM CST on “New Advances in #ExtracellularVesicle miRNA Research Using High-Throughput Affinity Capture”.
Join us through the link:

https://t.co/4GmBw6nQmW

[Leearne Hinch @leearnehinch]

Excited to welcome @DavidJ_Williams as @INOVIQLtd new Chairman, effective 29/11/23. David's strategic, corporate and financial markets experience will be invaluable as we advance the commercialisation of our #Exosome platform and SubB2M #cancer #diagnostics.

[INOVIQ Ltd (ASX:IIQ) @INOVIQLtd]

.@INOVIQLtd has appointed David Williams as Non-Exec Director and Chairman Elect. He brings extensive corporate and financial-markets experience to $IIQ as we advance our SubB2M cancer #diagnostics and commercialisation of our #exosome technologies https://t.co/k3VI6WxyYb

[Leearne Hinch @leearnehinch]

Congratulations to Professor Greg Rice for receiving this prestigious award that recognises his enormous contribution and leadership, both in the field of placentology and in the broader scientific community.

#diagnostics #exosome #research

[INOVIQ Ltd (ASX:IIQ) @INOVIQLtd]

.@INOVIQLtd CSO Prof Gregory Rice gave the opening address at @IFPA_Official 2023 as he received the Joan Hunt Senior Award in Placentology, the highest distinction of the international #placental research. Congrats from all at INOVIQ to Prof Rice. https://t.co/sbHfjXWUmQ $IIQ

[IR Department @ir_department]

In recognition of #IWD2022, we spoke to some of the inspiring women we work with and invited them to share their views on how we can all take action for a gender equal world in order to #BreakTheBias
https://t.co/fYOBTHKirA

[INOVIQ Ltd (ASX:IIQ) @INOVIQLtd]

February is #OvarianCancerAwarenessMonth. Ovarian cancer is the eighth most common cancer in women in Australia. Early detection and prevention is key to survival so this February learn more about #ovariancancer in our short video and at
@OvarianCancerOz #earlydetection

[INOVIQ Ltd (ASX:IIQ) @INOVIQLtd]

$IIQ has received new funding from @MTPConnect_AUS's Biomedical Translation Bridge (BTB) program, which will be used to develop proprietary monoclonal #antibodies for use in SubB2M #immunoassays for cancer detection. Read more here https://t.co/8mAaWi4kbU

[INOVIQ Ltd (ASX:IIQ) @INOVIQLtd]

ANNOUNCEMENT: @BARD1LSL is changing its name to INOVIQ. The new name INOVIQ represents ‘intelligent innovation’ as the Company builds an innovative portfolio of diagnostic and exosome-based products. Full release here: https://t.co/ERhW2LTZte #INOVIQ

[INOVIQ Ltd (ASX:IIQ) @INOVIQLtd]

CEO Dr Leearne Hinch will be presenting today on Day 2 of the Bell Potter Healthcare Conference on @BARD1LSL's pipeline and vision for early cancer detection.

View the presentation here: https://t.co/x5xRJwxgku

#BellPotter #earlydetection #cancer #HealthcareConference2021

[Leearne Hinch @leearnehinch]

@BARD1LSL has now achieved POC for transferring its SubB2M test to a simple, fast and inexpensive ELISA (immunoassay) format.

[INOVIQ Ltd (ASX:IIQ) @INOVIQLtd]

Achievement of this key proof-of-concept milestone supports and de-risks advancing the development of @BARD1LSL's SubB2M ELISA tests for #ovarian, #breast, #prostate and other #cancers.
Read the full release here: https://t.co/VjS1O6Odr0

[Leearne Hinch @leearnehinch]

@BARD1LSL is pleased to be presenting our next generation exosome capture tool EXO-NET and exhibiting at #ISEV2021.